Study to Determine the Efficacy and Safety of TG-C in Subjects With Kellgren/Lawrence Grade 2 or 3 OA of the Knee
Public ClinicalTrials.gov record NCT03291470. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase 3 Study to Determine the Efficacy and Safety of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 Osteoarthritis of the Knee
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A randomized, double-blind, placebo-controlled, multi-center, phase 3 study to determine the efficacy and safety of TG-C in subjects with Kellgren and Lawrence Grade 2 or 3 Osteoarthritis of the Knee, Osteoarthritis Research Society International (OARSI) medial joint space narrowing (JSN) Grade 1 or 2 of the knee joint. TG-C is to be administered by a single intra-articular injection to the damaged joint area via ultrasound guidance. Patients will be followed for 24 months for safety and efficacy.
Study identification
- NCT ID
- NCT03291470
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 531 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 9, 2021 (Actual)
- Primary completion
- Mar 6, 2024 (Actual)
- Completion
- May 1, 2026 (Actual)
- Last update posted
- Aug 20, 2026
2021 – 2026
United States locations
- U.S. sites
- 27
- U.S. states
- 14
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Nebojsa Skrepnik | Tucson | Arizona | 85712 | — |
| Steve Sitar | Anaheim | California | 92801 | — |
| Stuart Silverman | Beverly Hills | California | 90211 | — |
| Samy Metyas | Covina | California | 91722 | — |
| Bassil Aish | Huntington Beach | California | 92647 | — |
| Peter Hanson | La Mesa | California | 91942 | — |
| Duane Anderson | San Diego | California | 92120 | — |
| Miguel Trevino | Clearwater | Florida | 33756 | — |
| Jan Hommen | Doral | Florida | 33126 | — |
| Mira Baron | West Palm Beach | Florida | 33409 | — |
| Richard Radnovich | Boise | Idaho | 83713 | — |
| Thomas Schnitzer | Chicago | Illinois | 60611 | — |
| Nathan Rimmke | Rochester Hills | Michigan | 48307 | — |
| Larkin Wadsworth | St Louis | Missouri | 63141 | — |
| Robby Ann Quintos | Las Vegas | Nevada | 89109 | — |
| Igor Grosman | Brooklyn | New York | 11235 | — |
| Jonathan Samuels | New York | New York | 10016 | — |
| Minal Desai | Durham | North Carolina | 27704 | — |
| Jeremy Hoff | Wilmington | North Carolina | 28412 | — |
| Priyesh Mehta | Dayton | Ohio | 45432 | — |
| Edward Tavel | Charleston | South Carolina | 29406 | — |
| Durga Tanneru | Dallas | Texas | 75230 | — |
| Manjoo Sharma | Lewisville | Texas | 75057 | — |
| Haresh Boghara | Red Oak | Texas | 75154 | — |
| Leonel Reyes | San Antonio | Texas | 78215 | — |
| Lisa Blair | San Antonio | Texas | 78229 | — |
| David Scott | Spokane | Washington | 99218 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03291470, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 20, 2026 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03291470 live on ClinicalTrials.gov.